Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111


Design, synthesis, and biological evaluation of tetrazole analogs of Cl-amidine as protein arginine deiminase inhibitors.

Subramanian V, Knight JS, Parelkar S, Anguish L, Coonrod SA, Kaplan MJ, Thompson PR.

J Med Chem. 2015 Feb 12;58(3):1337-44. doi: 10.1021/jm501636x. Epub 2015 Jan 16.


Synthesis and screening of a haloacetamidine containing library to identify PAD4 selective inhibitors.

Jones JE, Slack JL, Fang P, Zhang X, Subramanian V, Causey CP, Coonrod SA, Guo M, Thompson PR.

ACS Chem Biol. 2012 Jan 20;7(1):160-5. doi: 10.1021/cb200258q. Epub 2011 Oct 21.


D-amino acid based protein arginine deiminase inhibitors: Synthesis, pharmacokinetics, and in cellulo efficacy.

Bicker KL, Anguish L, Chumanevich AA, Cameron MD, Cui X, Witalison E, Subramanian V, Zhang X, Chumanevich AP, Hofseth LJ, Coonrod SA, Thompson PR.

ACS Med Chem Lett. 2012 Oct 26;3(12):1081-1085.


Substrate specificity and kinetic studies of PADs 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3.

Knuckley B, Causey CP, Jones JE, Bhatia M, Dreyton CJ, Osborne TC, Takahara H, Thompson PR.

Biochemistry. 2010 Jun 15;49(23):4852-63. doi: 10.1021/bi100363t.


Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization.

Luo Y, Arita K, Bhatia M, Knuckley B, Lee YH, Stallcup MR, Sato M, Thompson PR.

Biochemistry. 2006 Oct 3;45(39):11727-36.


The development of N-α-(2-carboxyl)benzoyl-N(5)-(2-fluoro-1-iminoethyl)-l-ornithine amide (o-F-amidine) and N-α-(2-carboxyl)benzoyl-N(5)-(2-chloro-1-iminoethyl)-l-ornithine amide (o-Cl-amidine) as second generation protein arginine deiminase (PAD) inhibitors.

Causey CP, Jones JE, Slack JL, Kamei D, Jones LE, Subramanian V, Knuckley B, Ebrahimi P, Chumanevich AA, Luo Y, Hashimoto H, Sato M, Hofseth LJ, Thompson PR.

J Med Chem. 2011 Oct 13;54(19):6919-35. doi: 10.1021/jm2008985. Epub 2011 Sep 16. Erratum in: J Med Chem. 2011 Nov 24;54(22):7942.


A fluoroacetamidine-based inactivator of protein arginine deiminase 4: design, synthesis, and in vitro and in vivo evaluation.

Luo Y, Knuckley B, Lee YH, Stallcup MR, Thompson PR.

J Am Chem Soc. 2006 Feb 1;128(4):1092-3.


Development and use of clickable activity based protein profiling agents for protein arginine deiminase 4.

Slack JL, Causey CP, Luo Y, Thompson PR.

ACS Chem Biol. 2011 May 20;6(5):466-76. doi: 10.1021/cb1003515. Epub 2011 Feb 7.


N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis.

Willis VC, Gizinski AM, Banda NK, Causey CP, Knuckley B, Cordova KN, Luo Y, Levitt B, Glogowska M, Chandra P, Kulik L, Robinson WH, Arend WP, Thompson PR, Holers VM.

J Immunol. 2011 Apr 1;186(7):4396-404. doi: 10.4049/jimmunol.1001620. Epub 2011 Feb 23.


Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor.

Chumanevich AA, Causey CP, Knuckley BA, Jones JE, Poudyal D, Chumanevich AP, Davis T, Matesic LE, Thompson PR, Hofseth LJ.

Am J Physiol Gastrointest Liver Physiol. 2011 Jun;300(6):G929-38. doi: 10.1152/ajpgi.00435.2010. Epub 2011 Mar 17.


Development of a Selective Inhibitor of Protein Arginine Deiminase 2.

Muth A, Subramanian V, Beaumont E, Nagar M, Kerry P, McEwan P, Srinath H, Clancy K, Parelkar S, Thompson PR.

J Med Chem. 2017 Apr 13;60(7):3198-3211. doi: 10.1021/acs.jmedchem.7b00274. Epub 2017 Mar 31.


Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential.

Jones JE, Causey CP, Knuckley B, Slack-Noyes JL, Thompson PR.

Curr Opin Drug Discov Devel. 2009 Sep;12(5):616-27. Review.


The induction of microRNA-16 in colon cancer cells by protein arginine deiminase inhibition causes a p53-dependent cell cycle arrest.

Cui X, Witalison EE, Chumanevich AP, Chumanevich AA, Poudyal D, Subramanian V, Schetter AJ, Harris CC, Thompson PR, Hofseth LJ.

PLoS One. 2013;8(1):e53791. doi: 10.1371/journal.pone.0053791. Epub 2013 Jan 7.


Peptidomimetics as protein arginine deiminase 4 (PAD4) inhibitors.

Trabocchi A, Pala N, Krimmelbein I, Menchi G, Guarna A, Sechi M, Dreker T, Scozzafava A, Supuran CT, Carta F.

J Enzyme Inhib Med Chem. 2015 Jun;30(3):466-71. doi: 10.3109/14756366.2014.947976. Epub 2014 Sep 8.


Inhibitors of protein arginine deiminases and their efficacy in animal models of multiple sclerosis.

Sarswat A, Wasilewski E, Chakka SK, Bello AM, Caprariello AV, Muthuramu CM, Stys PK, Dunn SE, Kotra LP.

Bioorg Med Chem. 2017 May 1;25(9):2643-2656. doi: 10.1016/j.bmc.2017.03.006. Epub 2017 Mar 6.


Theoretical study of the mechanism of protein arginine deiminase 4 (PAD4) inhibition by F-amidine.

Li D, Liu C, Lin J.

J Mol Graph Model. 2015 Feb;55:25-32. doi: 10.1016/j.jmgm.2014.10.014. Epub 2014 Nov 7.


Peptidylarginine deiminases: novel drug targets for prevention of neuronal damage following hypoxic ischemic insult (HI) in neonates.

Lange S, Rocha-Ferreira E, Thei L, Mawjee P, Bennett K, Thompson PR, Subramanian V, Nicholas AP, Peebles D, Hristova M, Raivich G.

J Neurochem. 2014 Aug;130(4):555-62. doi: 10.1111/jnc.12744. Epub 2014 May 24.


Identification of multiple structurally distinct, nonpeptidic small molecule inhibitors of protein arginine deiminase 3 using a substrate-based fragment method.

Jamali H, Khan HA, Stringer JR, Chowdhury S, Ellman JA.

J Am Chem Soc. 2015 Mar 18;137(10):3616-21. doi: 10.1021/jacs.5b00095. Epub 2015 Mar 5.


Inhibitors of acyl-CoA:cholesterol O-acyltransferase. synthesis and pharmacological activity of (+/-)-2-dodecyl-alpha-phenyl-N-(2,4,6-trimethoxyphenyl)-2H-tetrazole-5- acetamide and structurally related tetrazole amide derivatives.

O'Brien PM, Sliskovic DR, Picard JA, Lee HT, Purchase CF 2nd, Roth BD, White AD, Anderson M, Mueller SB, Bocan T, Bousley R, Hamelehle KL, Homan R, Lee P, Krause BR, Reindel JF, Stanfield RL, Turluck D.

J Med Chem. 1996 Jun 7;39(12):2354-66.


Molecular targeting of protein arginine deiminases to suppress colitis and prevent colon cancer.

Witalison EE, Cui X, Causey CP, Thompson PR, Hofseth LJ.

Oncotarget. 2015 Nov 3;6(34):36053-62. doi: 10.18632/oncotarget.5937.

Supplemental Content

Support Center